186 related articles for article (PubMed ID: 16906456)
1. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease.
Lockwood P; Ewy W; Hermann D; Holford N
Pharm Res; 2006 Sep; 23(9):2050-9. PubMed ID: 16906456
[TBL] [Abstract][Full Text] [Related]
2. Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.
Lehr T; Staab A; Trommeshauser D; Schaefer HG; Kloft C
AAPS J; 2010 Jun; 12(2):117-29. PubMed ID: 20077053
[TBL] [Abstract][Full Text] [Related]
3. How modeling and simulation have enhanced decision making in new drug development.
Miller R; Ewy W; Corrigan BW; Ouellet D; Hermann D; Kowalski KG; Lockwood P; Koup JR; Donevan S; El-Kattan A; Li CS; Werth JL; Feltner DE; Lalonde RL
J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):185-97. PubMed ID: 16283534
[TBL] [Abstract][Full Text] [Related]
4. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
[TBL] [Abstract][Full Text] [Related]
5. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
6. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
[TBL] [Abstract][Full Text] [Related]
7. Quantification of disease progression and dropout for Alzheimer's disease.
William-Faltaos D; Chen Y; Wang Y; Gobburu J; Zhu H
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):120-31. PubMed ID: 23211395
[TBL] [Abstract][Full Text] [Related]
8. Hierarchical Bayesian cognitive processing models to analyze clinical trial data.
Shankle WR; Hara J; Mangrola T; Hendrix S; Alva G; Lee MD
Alzheimers Dement; 2013 Jul; 9(4):422-8. PubMed ID: 23123230
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
Wilkinson D; Windfeld K; Colding-Jørgensen E
Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016
[TBL] [Abstract][Full Text] [Related]
10. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
[TBL] [Abstract][Full Text] [Related]
11. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks.
Bowen RL; Perry G; Xiong C; Smith MA; Atwood CS
J Alzheimers Dis; 2015; 44(2):549-60. PubMed ID: 25310993
[TBL] [Abstract][Full Text] [Related]
12. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.
Rockwood K; Fay S; Gorman M; Carver D; Graham JE
BMC Neurol; 2007 Aug; 7():26. PubMed ID: 17760991
[TBL] [Abstract][Full Text] [Related]
13. An adaptive optimal design for the E(max) model and its application in clinical trials.
Leonov S; Miller S
J Biopharm Stat; 2009; 19(2):360-85. PubMed ID: 19212886
[TBL] [Abstract][Full Text] [Related]
14. Model-based drug development.
Lalonde RL; Kowalski KG; Hutmacher MM; Ewy W; Nichols DJ; Milligan PA; Corrigan BW; Lockwood PA; Marshall SA; Benincosa LJ; Tensfeldt TG; Parivar K; Amantea M; Glue P; Koide H; Miller R
Clin Pharmacol Ther; 2007 Jul; 82(1):21-32. PubMed ID: 17522597
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
16. Impact of trial design on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors.
Larsen MS; Juul RV; Kreilgaard M; Kristensen AT; Simonsson USH
Eur J Pharm Sci; 2018 Oct; 123():531-538. PubMed ID: 30077714
[TBL] [Abstract][Full Text] [Related]
17. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
18. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.
Bullock R; Erkinjuntti T; Lilienfeld S;
Dement Geriatr Cogn Disord; 2004; 17(1-2):29-34. PubMed ID: 14560062
[TBL] [Abstract][Full Text] [Related]
19. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
[TBL] [Abstract][Full Text] [Related]
20. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles.
Le Bars PL
Pharmacopsychiatry; 2003 Jun; 36 Suppl 1():S50-5. PubMed ID: 13130389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
